A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

This study tests a drug called XER-001 (a modified form of amifostine, a cell-protecting medication) delivered through a tube into the small intestine, combined with a precise radiation therapy called stereotactic body radiation therapy (SBRT), for people with locally advanced pancreatic cancer that cannot be surgically removed. **You may be eligible if...** - You have a confirmed diagnosis of pancreatic adenocarcinoma (a specific type of pancreatic cancer) - Your tumor has been determined to be unresectable (cannot be surgically removed) or you are not a candidate for surgery due to other health conditions - There is no evidence of cancer spread to distant organs - You are in good enough physical condition to tolerate radiation therapy **You may NOT be eligible if...** - Your cancer has already spread to distant organs (metastatic) - Your tumor has grown into (invaded) the bowel - You are unwilling or unable to follow the study protocol Talk to your doctor to see if this trial is right for you.